Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.
Biogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Disease (AD) drug aducanumab with the FDA.
The European Commission has conditionally approved Gilead’s remdesivir for treatment of COVID-19, the first drug officially cleared for use against the disease by EU regulators.
The UK’s pharmaceutical industry has published headline figures from its Disclosure UK scheme, showing payments from pharma to healthcare professionals increased in 2019.
